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We describe the first reported outbreak of West Nile 
virus (WNV) infection in humans in Serbia in August 
to October 2012 and examine the association of vari-
ous variables with encephalitis and fatal outcome. 
Enzyme-linked immunosorbent assay (ELISA) was 
used for detection of WNV-specific IgM and IgG anti-
bodies in sera and cerebrospinal fluid. A total of 58 
patients (mean age: 61 years; standard deviation: 15) 
were analysed: 44 were from Belgrade and its suburbs; 
52 had neuroinvasive disease, of whom 8 had menin-
gitis, while 44 had encephalitis. Acute flaccid paraly-
sis developed in 13 of the patients with encephalitis. 
Age over 60 years and immunosuppression (includ-
ing diabetes) were independently associated with the 
development of encephalitis in a multivariate analysis: 
odds ratio (OR): 44.8 (95% confidence interval (CI): 
4.93–408.59); p=0.001 (age over 60 years); OR: 10.76 
(95% CI: 1.06–109.65); p=0.045 (immunosuppres-
sion including diabetes). Respiratory failure requiring 
mechanical ventilation developed in 13 patients with 
encephalitis. A total of 35 patients had completely 
recovered by the time they were discharged; nine 
patients died. The presence of acute flaccid paraly-
sis, consciousness impairment, respiratory failure and 
immunosuppression (without diabetes) were found 
to be associated with death in hospital in a univari-
ate analysis (p<0.001, p=0.007, p<0.001 and p=0.010, 
respectively).
Introduction
West Nile Virus (WNV) is a single-stranded RNA, 
mosquito-borne virus that belongs to the Flaviviridae 
family. It was first identified in the West Nile district 
of Uganda in 1937 in a woman who presented with a 
mild febrile illness [1]. During the next decades, the 
virus spread through Africa and Asia: by the mid-
20th century, it had appeared in Europe [2]. The first 
cases were reported in Israel (in the World Health 
Organization European Region) in the 1950s, followed 
by France in 1962–63 [2]. The first large outbreak in 
humans in Europe was in Romania, in 1996–97, and 
subsequent outbreaks were also reported in Russia 
in 1999 and Spain in 2004 [3-5]. Recently, ecological 
conditions were favourable for the spread of WNV in 
the Mediterranean, central and south-east Europe, 
causing outbreaks in countries neighbouring Serbia: 
Italy in 2008–10, Hungary in 2008, Albania and the 
former Yugoslav Republic of Macedonia in 2011 [6-9]. 
In Greece in 2010, 262 cases of WNV human infection 
were reported, including 197 patients with neuroinva-
sive disease [10]. In the following year (2011), there 
was another outbreak in Greece [11]. At the same time, 
epidemics were recorded in Turkey in 2010 and 2011, 
and Russia in 2010 [12,13]. Taken together, these data 
indicated that WNV was circulating in nearby countries, 
suggesting that human cases of WNV infection could 
be expected in Serbia as well. In 2011, Lupulovic et al. 
reported the first serological evidence of WNV infec-
tion in Serbia as a zoonosis: they showed that 42 (12%) 
of 349 horses analysed had WNV-specific neutralising 
antibodies [14].
It was first thought that WNV caused a mild, influenza-
like disease, but the epidemics in Romania in 1996–97 
and New York in 1999 demonstrated that this virus was 
also a neuropathogen, causing severe neurological 
disease [3,15]. Today, it is known that around 20% of 
people who become infected have symptomatic dis-
ease, and one of 150 infected has neuroinvasive dis-
ease, which can present as meningitis, encephalitis 
and acute flaccid paralysis (AFP) [16,17]. The clinical 
presentation of AFP usually resembles that of poliomy-
elitis and AFP has been recognised as a separate entity 
of neuroinvasive disease due to WNV infection [16]. 
Possible, but extremely rare, clinical presentations of 
WNV infection are chorioretinitis, pancreatitis, fulmi-
nant hepatitis and myocarditis [18-20]. 
We describe here the clinical and epidemiological char-
acteristics and outcome of patients in the first reported 
outbreak of WNV infection in humans in Serbia in 2012. 
We also sought to determine the association of various 





At the Clinic for Infectious and Tropical Diseases, 
Clinical Centre Serbia in Belgrade, we carry out specific 
screening for WNV infection (we have no data about 
specific screening in other medical centres in Serbia). 
In the study presented here, we enrolled patients with 
acute WNV infection treated at our clinic from 1 August 
to 31 October 2012. 
Case definition
Diagnostic criteria for probable and confirmed cases 
were established according to the European Union case 
definition for West Nile fever [21]. A person with fever 
(≥37.5 °C), meningitis or encephalitis met the clinical 
criteria. 
Patients presenting with meningitis, encephalitis and/
or AFP were considered as having neuroinvasive dis-
ease. Meningitis was defined as the presence of fever, 
clinical signs of meningeal inflammation, including 
headache, nuchal rigidity, Kernig’s sign or Brudzinski 
signs, photophobia or phonophobia, and the presence 
of cerebrospinal fluid (CSF) pleocytosis (>5 leucocytes/
mm3; norm: 0–5 leucocytes/mm3), elevated protein lev-
els (>0.45 g/L; norm: 0.15–0.45 g/L) and normal (2.6–
3.1 mmol/L, 50–60% of serum glucose levels) or mildly 
decreased (2.4–2.6mmol/L) CSF glucose level [22,23]. 
Encephalitis was defined as the presence of fever, 
encephalopathy (decreased or altered level of con-
sciousness, lethargy or personality change) and/or 
focal neurological signs (weakness, cranial nerve pal-
sies), seizures or movement disorders (tremor, parkin-
sonism, ataxia) and the presence of CSF pleocytosis (>5 
leucocytes/mm3), elevated protein levels (>0.45 g/L), 
and normal (2.6–3.1 mmol/L, 50–60% of serum glu-
cose levels) or mildly decreased (2.4–2.6mmol/L) CSF 
glucose level [22,23]. 
AFP was defined as acute onset of limb weakness or 
paralysis with progression over 48 hours. Limb weak-
ness was characterised by at least two of the following: 
asymmetry; areflexia/hyporeflexia of affected limbs; 
absence of pain; electrodiagnostic studies consist-
ent with an anterior horn cell lesion; CSF pleocytosis 
(>5 leucocytes/mm3) and elevated protein levels (>0.45 
g/L) [22]. 
Laboratory criteria for case confirmation was the pres-
ence of at least one of the following: (i) isolation of WNV 
from blood or CSF; (ii) detection of WNV nucleic acid 
in blood or CSF; (iii) WNV-specific antibody response 
(IgM) in CSF; (iv) WNV IgM high titre and detection of 
WNV IgG, and confirmation by neutralisation [21]. 
In our study, all patients who were diagnosed as 
confirmed cases had a WNV-specific IgM antibody 
response in CSF. Isolation of the virus and reverse 
transcription-polymerase chain reaction (RT-PCR) for 
detection of WNV nucleic acid were not performed. 
Laboratory criteria for a probable case were the pres-
ence of WNV-specific IgM and IgG antibody response in 
serum in the absence of WNV-specific IgM antibodies 
in CSF. 
None of the patients had a history of flavivirus vaccina-
tion. All of the patients with neuroinvasive disease had 
sterile CSF bacterial cultures and negative serological 
tests for other common causes of viral encephalitis, 
especially herpes viruses. 
Figure 1













































































































Acute phase CSF and acute and convalescence phase 
serum samples (on the first day of hospitalisation and 
within 10–14 days after symptom onset) were collected 
to be tested for the presence of IgM and IgG WNV-
specific antibodies. The samples were transported at 
4 °C and stored at −25 °C until testing. Samples were 
analysed by enzyme-linked immunosorbent assay 
(ELISA) (Anti-West Nile Virus ELISA (IgM) and  Anti-
West Nile Virus ELISA (IgG), EUROIMMUN, Medizinische 
Labordiagnostika AG), which was performed by the 
National Reference Laboratory for Arboviruses of the 
Institute of Virology, Vaccines and Sera ‘Torlak’ in 
Belgrade. 
Patient data
Patients’ demographic characteristics (age, sex, 
region of residence within the country), comorbid-
ity (hypertension, cardiovascular disease including 
cardiomyopathy, coronary disease, previous stroke 
and myocardial infarction, diabetes, immunosuppres-
sion), presenting symptoms and signs, clinical find-
ings, biochemical analysis of blood and CSF along 
with the results of serological tests were recorded, 
as well as the functional outcome at hospital dis-
charge. Immunosuppression was defined as a state of 
reduced immune response due to, for example, immu-
nosuppressive therapy, malignancy and radiotherapy. 
Consciousness impairment was classified as mild if the 
Glasgow Coma Score (GCS) was >8, and serious if the 
GCS was ≤8. 
Statistical analyses
All data were analysed using descriptive and analytical 
statistics. For the univariate analysis, chi-square test 
and Fisher’s exact test were applied for categorical 
variables and Student’s t-test for continuous variables. 
Binary logistic regression analysis was performed to 
estimate the independent association of several vari-
ables with the development of encephalitis. Covariates 
were selected for entry into the model based on the 
results of univariate analysis (p<0.2) and judgement 
of clinical importance (i.e. if a known risk factor for 
encephalitis). Odds ratios (ORs) and 95% confidence 
intervals (CIs) were obtained. 
The association of several variables with fatal outcome 
was analysed using univariate analysis: multivariate 
analysis could not be performed due to the small num-
ber of deaths. The Statistical Package for the Social 
Sciences (SPSS) software for Windows (version 17.0) 
was used for statistical analysis. Statistical signifi-
cance was set at 0.05.
Results
A total of 58 patients who met the diagnostic criteria 
were included in our study. Of these, 45 were diag-
nosed as confirmed cases and 13 as probable cases, 
according to the case definition. The first cases had 
symptom onset in the beginning of August 2012 and 
the last in the first half of October (Figure 1). 
Of the 58 patients, 32 reported spending prolonged 
periods of time outdoors (every day during the sum-
mer, for more than two hours per day) or close (500 
metres) to a river, or living next to a river and all had 
had multiple mosquito bites in the three weeks before 
symptom onset. 
The majority of patients (n=33) were from Belgrade; 
11 others were from Belgrade suburbs. A further seven 
were from the district of Srem, six from South Banat 
and one from North Banat (Figure 2). The first diag-
nosed case of WNV infection was in Pancevo, in South 
Banat. None of the patients had travelled abroad in 
the four weeks before symptom onset, except for one 
patient who had travelled to Montenegro (17 days 
before symptom onset), where no human cases of WNV 
infection had been reported. 
Most patients (n=52) had neuroinvasive disease, while 
six presented with mild acute febrile illness. Among 
the six, three presented with fever and maculopapular 
Figure 2
Distribution of human cases of West Nile virus infection, 
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rash, one patient had pneumonia and two had a pro-
longed febrile illness with intensive myalgia.
Of the 52 patients with neuroinvasive disease, 44 had 
encephalitis and 8 meningitis. Of those with encepha-
litis, 10 presented with ataxia and dysmetria, suggest-
ing rhombencephalitis, while 13 had AFP affecting one 
or more limbs. There were no patients with AFP without 
encephalitis.
The mean age of all 58 patients was 61 years (standard 
deviation: 15), while 33/44 patients with encephalitis 
were over 60 years old (Table 1). Patients with enceph-
alitis were statistically significantly older than those 
with mild febrile illness or meningitis (p<0.0001). Age 
over 60 years and immunosuppresion including diabe-
tes were found to be associated with the development 
of encephalitis by univariate analysis (p<0.0001 and 
p=0.024, respectively; Table 1), and were confirmed to 
be independently associated with encephalitis by mul-
tivariate logistic regression analysis after adjustment 
for confounders (sex, cardiovascular disease, hyper-
tension) (OR: 44.8; 95% CI: 4.93–408.59; p =0.001 (age 
over 60 years) and OR: 10.76; 95% CI: 1.06–109.65; 
p=0.045 (immunosuppression including diabetes)).
Cytological and biochemical analysis of CSF from the 
52 patients with neuroinvasive disease revealed pleo-
cytosis (mean: 145 leucocytes/mm3 (SD: 124), with lym-
phocyte predominance in 38 patients. In all 52 patients 
with neuroinvasive disease, the protein level was 
mildly elevated, at a mean of 1.09 g/L (SD: 0.52) and 
the mean glucose level was normal. 
The frequency of self-reported symptoms and clinical 
signs in the 52 patients with neuroinvasive disease are 
shown in Table 2.
Among patients with encephalitis, neurological mani-
festations, including focal neurological deficit and/or 
consciousness impairment, were recorded a mean of 
4 days (SD: 3) after symptom onset. Consciousness 
impairment appeared from the first to the 10th day 
of illness (median: 4th day). Among 33 patients who 
developed an altered state of consciousness, 13 had 
qualitative consciousness impairment (disorientation, 
confusion, agitation), while the others also had quanti-
tative consciousness impairment (somnolence, sopor, 
coma). Six of the 33 had severe consciousness impair-
ment (GCS≤8).
Respiratory failure requiring mechanical ventilation 
developed in 13 patients with encephalitis a mean of 
12 days (SD: 6) after symptom onset (median: 11 days; 
range: 3–21). Five of these patients had only mild or 
no quantitative consciousness impairment at the time 
respiratory failure occurred. The mean duration of 
mechanical ventilation was 11 days (SD: 17) (median: 4 
days; range: 2–50 days). 
Of the 58 patients, 35 had completely recovered by the 
time they were discharged (Figure 3). Nine patients 
died. 
All patients who died had encephalitis: eight of the 
nine were over 60 years-old. The presence of acute 
flaccid paralysis, consciousness impairment, respira-
tory failure and immunosuppresion (without diabetes) 
Table 1






















Mean age (SD) 61 (15) 40 (13) 54 (10) 48 (13) 65 (13) <0.001 – – –
Aged >60 years 34 0 1 1 33 <0.001 39.0 (4.6–333.3) 0.001
44.8 
(4.9–408.6
Male 40 3 5 8 32 0.210 2 (0.6–7.0) – –
Immunosuppression 






excluding diabetes 5 0 0 0 5 0.237 – – –
Hypertension 33 0 6 6 27 0.182 2.1 (0.7–7.2) – –
Cardiovascular 
disease 11 0 1 1 10 0.186
3.8 
(0.4–32.9) – –
CI: confidence interval; OR: odds ratio; SD: standard deviation.
a Univariate analysis was performed to evaluate the difference between patients with encephalitis and those with other forms of the infection 
(meningitis, mild febrile illness).
b Multivariate logistic regression analysis was performed after adjustment for confounders (sex, cardiovascular disease, hypertension).
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were found to be associated with a fatal outcome in 
a univariate analysis (p<0.001, p=0.007, p<0.001 and 
p=0.010, respectively) (Table 3).
Discussion
In Serbia, the summer of 2012 was among the warmest 
summers in recent years, with a dense mosquito popu-
lation leading to the appearance of the first cases of 
human WNV infection in the country [24]. The majority 
of the patients were from urban regions, mainly from 
Belgrade and its suburbs, possibly due to specific 
screening in our clinic. It could also be related to the 
fact that Belgrade is situated at the confluence of two 
rivers (Danube and Sava). People enjoy swimming and 
other leisure activities (10–50 metres from the rivers) 
during the summer months and there is also a large 
number of houses on stilts and boat restaurants where 
many people gather in the summer evenings: there 
are dense mosquito populations by the rivers, espe-
cially in the evening [25]. Although epidemics of WNV 
infection were first reported in rural areas, the epidem-
ics in Romania in 1996 and New York, United States, 
in 1999 demonstrated the spread of this infection in 
urban areas as well [3,15]. In our study, the majority of 
diagnosed patients had neuroinvasive disease, but we 
assume that there were more patients with WNV infec-
tion who had influenza-like febrile disease, but who 
did not seek medical help due to the symptoms being 
mild or were treated in primary care. 
During the outbreaks in Israel, New York and Romania, 
most of those diagnosed with WNV infection had 
neuroinvasive disease [2,3,15,26]. In our study popu-
lation, encephalitis was the most frequent form (in 
44 of 58 patients). Similar results were reported in 
Romania (1996) and the United States (1999), with 
meningoencephalitis being present in 60–65% of 
patients with WNV infection with neuroinvasive dis-
ease [17]. In our study, encephalitis was seen mainly 
in older people and those with any kind of immunosu-
pression including diabetes, which was also reported 
by Nash et al. and Murray et al. [15,27]. 
A notable proportion of our patients with neuroin-
vasive disease developed AFP. In the outbreaks and 
Romania and Russia, paresis or paralysis was recorded 
in 15–20% of patients, while in the New York epidem-
ics, the proportion of patients with paresis was notably 
higher, reaching 50%, while about 10% had paralysis 
[3,4,15,26].
Another symptom that was observed more often in 
patients with encephalitis due to WNV infection com-
pared with patients with encephalitis caused by other 
pathogens was respiratory failure and the need for 
ventilation support. In our patients, respiratory failure 
mostly developed during the later stages the illness, 
usually around the 12th day after symptom onset. 
Respiratory failure during encephalitis due to WNV 
infection has also been described by others [28,29]: it 
was usually not accompanied by consciousness impair-
ment profound enough to cause central respiratory 
failure [29]. It has been assumed that respiratory fail-
ure in neuroinvasive disease due to WNV infection is 
caused by respiratory muscle weakness including both 
diaphragm and intercostal muscles, similar to that in 
poliomyelitis [30,31]. Pathological inspection of the 
spinal cord of patients who had died from respiratory 
failure in WNV infection revealed gliosis, neuronal loss 
and inflammation in the anterior horns of the cervical 
spinal cord and brainstem [32].
The case fatality rate (CFR) of 16% (9/58) in our study 
is similar to CFRs reported in the literature for WNV 
infection. In recent epidemics, the overall CFR was 
lower, ranging from 4% to 14%, but higher rates were 
found in older patients and those with encephalitis 
[4,15,20,26,33,34]. Among patients with encephalitis, 
the CFR reached 18% in the United States and 24% in 
Israel, while CFR among patients of age over 70 years 
was 29% [15,26]. High rates of patients with encepha-
litis, AFP and fatal outcome were usually observed in 
the first outbreaks, when the virus was introduced to 
a non-immune population [15,26]. In our study, the CFR 
reached 20% (9/44) in patients with encephalitis. 
Veterinary and entomological investigations related to 
WNV have also been performed in our country. Djuricic 
et al. analysed 3,618 sera collected from several ani-
mal species and humans from different areas of Serbia 
in 2008–12, revealing that WNV was circulating in 9 of 
18 tested locations in Serbia [35]. The percentage of 
seropositive results varied from 0.42% in Pozarevac 
(horses and humans) to 6.45% in Novi Pazar (dogs). 
Among the species tested, the highest seropositiv-
ity was registered in horses (3.97%) [35]. Petrovic et 
al. examined 92 sera from 30 migratory and resident 
Table 2
Frequency of self-reported symptoms and clinical signs in 
patients with neuroinvasive disease due to West Nile virus 
infection, Serbia, August-October 2012 (n=52)
Signs and symptoms Number of patients













wild birds species collected during 2012 in Vojvodina: 
WNV antibodies were detected in seven samples [36]. 
WNV RNA was also detected in birds, mostly among 
raptors: genetic analysis of isolated virus strains dem-
onstrated that they belonged to lineage II, similar to 
those detected in Greece and Hungary [36]. During 
August 2012, a total of 3,000 Culex pipiens mosquitoes 
were collected from three locations in Belgrade: test-
ing of 150 pools of females confirmed the presence of 
WNV nucleic acid in 10 of the pools [37]. Tests in vari-
ous parts of Serbia suggest that WNV is circulating 
not only in the area of Belgrade and Vojvodina [35]. 
Screening for human cases should therefore be further 
strengthened in summer and autumn in regions of the 
country not previously affected by WNV. In 2013, there 
were even more reported cases (n=260) [38], of which 
180 were treated in our clinic.
This study has some limitations. It was a single-cen-
tre study, and although it was performed at the main 
and largest clinic for infectious diseases in Serbia, 
there are other hospitals in which patients with WNV 
infection might have been treated. For this reason, no 
incidence rates could be calculated at a national or 
regional level. Another limitation is the small number 
of patients. While some of the results were statistically 
significant and concur with previous publications, the 
CIs of the ORs were wide. The study included only six 
patients with mild febrile illness, making it difficult to 
determine correlates of encephalitis. A larger sample 
size would be necessary for confirmation of the results. 
A case–control study comparing clinical characteristics 
of patients with encephalitis due to WNV infection with 
those of encephalitis patients with a different aetiol-
ogy would also provide more information and might 
reveal specific characteristics of encephalitis due to 
WNV infection. 
Given the number of patients with WNV infection in 
2012 in Serbia, a number of public health measures 
were undertaken. These included intensifying activi-
ties to reduce the number of mosquitoes in indoor 
and outdoor environments (e.g. using insecticides, 
destroying mosquito habitats), systematic extermina-
tion of larvae and adult forms of mosquitoes, educa-
tion of the population on how to avoid or decrease the 
risk of being bitten by potentially infected mosquitoes 
(e.g. through poster, leaflets, television and newspa-
pers) [37]. The Ministry of Health has set up a project 
to detect WNV in mosquitoes in Serbia. A team from 
the Institute for biocides and medical ecology – com-
prising physicians, veterinarians and laboratory staff 
–  will set traps to collect adult forms of mosquitoes, 
which will be tested for the presence of WNV (by RT- 
PCR) in urban regions and near large rivers in various 
parts of Serbia. Surveillance of human cases has also 
been improved as WNV infection became mandatorily 
notifiable, in August 2012.
Figure 3
Functional outcome of patients at hospital discharge according to different forms of West Nile virus infection, Serbia, 
August–October 2012 (n=58) 
The numbers represent the number of patients with the specified outcome.
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These actions should help avoid future outbreaks 
of human WNV infection and raise the awareness of 
healthcare providers about the emergence of the virus 
in Serbia. In patients with mild influenza-like disease of 
unknown origin and those with neuroinvasive disease 
during late summer and early autumn, WNV should be 
considered a possible causative pathogen.
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